Tag: anticoagulants
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis
The post-thrombotic syndrome frequently develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical... read more
Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding
Direct oral anticoagulants (DOACs) have expanded the armamentarium for antithrombotic therapy. Although DOAC-related major bleeding was associated with favorable outcomes compared with warfarin in clinical trials, warfarin... read more
Dose-Adjusted DOACs: What Efficacy vs Warfarin?
The direct oral anticoagulants (DOACs) offer distinct advantages over warfarin - among them, dose adjustment is only needed in cases of impaired renal function, advanced age, low body weight, or potential for drug-drug interactions.... read more
POCT for emergency assessment of coagulation in patients treated with direct oral anticoagulants
Hemochron Signature Point-of-care testing (POCT) can be a fast and reliable alternative for guiding emergency treatment during rivaroxaban and dabigatran therapy. It allows the rapid identification of a relevant fraction... read more
ACC Releases Afib Treatment Interruption Guidelines
Revised recommendations released today by the American College of Cardiology are designed to help clinicians determine if, and for how long, Afib patients on anticoagulants should be taken off the medications before scheduled... read more
Study Examines Rates, Causes of ED Visits for Adverse Drug Events
The prevalence of emergency department (ED) visits for adverse drug events (ADEs) in the United States was estimated to be four per 1,000 individuals in 2013 and 2014, and the most common drug classes involved were anticoagulants,... read more
Data from clinical registries can ID novel drug interactions
Data mining can be used to discover unknown drug-drug interactions in cardiovascular medicine, according to a study published online Nov. 8 in Circulation: Cardiovascular Quality and Outcomes.... read more
Baxter initiates late-stage study of novel therapy for acute kidney injury
Baxter International commences a Phase 3 clinical trial assessing an investigational drug, Prismocitrate 18, that combines a citrate anticoagulant and renal replacement solution.... read more
5 New Oral Anticoagulants for Atrial Fibrillation
When trying to decide which therapy for nonvalvular atrial fibrillation (NVAF) is optimal for patients, many factors should be considered, including compliance, ability to perform daily activities of living, and nutrition... read more
More NOAC Comparisons See More Bleeding With Rivaroxaban: Is the ‘Writing on the Wall’?
Evidence is mounting, albeit from observational studies, that while all of the non-vitamin K antagonist oral anticoagulants (NOACs) appear to have similar efficacy in terms of stroke reduction in atrial fibrillation, they... read more
